Nivolumab Plus Cabozantinib vs Sunitinib for First-Line Treatment of Advanced Renal Cell Carcinoma (aRCC): 3-Year Follow-Up From the Phase 3 CheckMate 9 ER Trial (vol 41, pg 603, 2023)

被引：0
|
作者：
Motzer, Robert J.
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 21期
关键词：
D O I：
10.1200/JCO.23.00901
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：3767 / 3767
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of nivolumab plus ipilimumab (N plus I) versus sunitinib (S) for first-line treatment of patients with advanced sarcomatoid renal cell carcinoma (sRCC) in the phase 3 CheckMate 214 trial with extended 5-year minimum follow-up.
    Tannir, Nizar M.
    Signoretti, Sabina
    Choueiri, Toni K.
    McDermott, David F.
    Motzer, Robert J.
    George, Saby
    Powles, Thomas
    Donskov, Frede
    Tykodi, Scott S.
    Pal, Sumanta K.
    Gupta, Saurabh
    Lee, Chung-Wei
    McHenry, M. Brent
    Rini, Brian I.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
  • [42] Avelumab plus axitinib vs sunitinib as first-line treatment of advanced renal cell carcinoma: Phase 3 study (JAVELIN Renal 101)
    Choueiri, Toni K.
    Rini, Brian I.
    Larkin, James M. G.
    Bjarnason, Georg A.
    Gravis, Gwenaelle
    Gurney, Howard
    Lee, Jae-Lyun
    Keizman, Daniel
    Haanen, John B. A. G.
    Tomita, Yoshihiko
    Uemura, Hirotsugu
    Albiges, Laurence
    Schmidinger, Manuela
    Atkins, Michael B.
    Mariani, Mariangela
    Shnaidman, Michael
    Di Pietro, Alessandra
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [43] Biomarker analyses from the phase III CheckMate 214 trial of nivolumab plus ipilimumab (N plus I) or sunitinib (S) in advanced renal cell carcinoma (aRCC).
    Motzer, Robert J.
    Choueiri, Toni K.
    McDermott, David F.
    Powles, Thomas
    Yao, Jin
    Ammar, Ron
    Papillon-Cavanagh, Simon
    Saggi, Shruti S.
    McHenry, Brent M.
    Ross-Macdonald, Petra
    Wind-Rotolo, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [44] Long-term follow-up on overall survival and independent review of response in CheckMate 214: first-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Grimm, M. -O.
    Tannir, N.
    McDermott, D.
    Escudier, B.
    Hammers, H.
    Aren Frontera, O.
    Plimack, E.
    Barthelemy, P.
    Neiman, V.
    George, S.
    Porta, C.
    Powles, T.
    Donskov, F.
    Amin, A.
    Tykodi, S.
    Tomita, Y.
    Rini, B.
    McHenry, M. B.
    Saggi, S. S.
    Motzer, R.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 208 - 208
  • [45] Overall survival and independent review of response in CheckMate 214 with 42-month follow-up: First-line nivolumab plus ipilimumab (N plus I) versus sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC)
    Tannir, Nizar M.
    McDermott, David F.
    Escudier, Bernard
    Hammers, Hans J.
    Aren, Osvaldo Rudy
    Plimack, Elizabeth R.
    Barthelemy, Philippe
    Neiman, Victoria
    George, Saby
    Porta, Camillo
    Powles, Thomas
    Donskov, Frede
    Grimm, Marc-Oliver
    Amin, Asim
    Tykodi, Scott S.
    Tomita, Yoshihiko
    Rini, Brian I.
    McHenry, M. Brent
    Saggi, Shruti Shally
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [46] Phase 3 study of avelumab in combination with axitinib versus sunitinib as first-line treatment for patients with advanced renal cell carcinoma (aRCC)
    Motzer, R. J.
    Choueiri, T.
    Larkin, J.
    Albiges, L.
    Haanen, J. B.
    Schmidinger, M.
    Atkins, M. B.
    Mariani, M.
    Shnaidman, M.
    Di Pietro, A.
    Rini, B. I.
    ANNALS OF ONCOLOGY, 2016, 27
  • [47] Dual immune checkpoint inhibition in metastatic renal cell carcinoma Editorial re.: Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced RCC: extended 4-year follow-up of the phase III CheckMate 214 trial
    Schmidinger, M.
    Shariat, S. F.
    Fajkovic, H.
    ESMO OPEN, 2021, 6 (01)
  • [48] Nivolumab plus ipilimumab versus sunitinib for fi rst-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
    Tannir, N. M.
    Albiges, L.
    Mcdermott, D. F.
    Burotto, M.
    Choueiri, T. K.
    Hammers, H. J.
    Barthelemy, P.
    Plimack, E. R.
    Portat, C.
    George, S.
    Donskov, F.
    Atkins, M. B.
    Gurney, H.
    Kollmannsberger, C. K.
    Grimm, M. -o.
    Barrios, C.
    Tomita, Y.
    Castellano, D.
    Gruenwald, V.
    Rini, B. I.
    Jiang, R.
    Desilva, H.
    Fedorov, V.
    Lee, C. -w.
    Motzer, R. J.
    ANNALS OF ONCOLOGY, 2024, 35 (11) : 1026 - 1038
  • [49] A phase 3, randomized, open-label study of nivolumab combined with cabozantinib vs sunitinib in patients with previously untreated advanced or metastatic renal cell carcinoma (RCC; CheckMate 9ER).
    Choueiri, Toni K.
    Apolo, Andrea B.
    Powles, Thomas
    Escudier, Bernard
    Aren, Osvaldo Rudy
    Shah, Amishi
    Kessler, Elizabeth Riley
    Hsieh, James J.
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [50] Final overall survival analysis and organ-specific target lesion assessments with two-year follow-up in CheckMate 9ER: Nivolumab plus cabozantinib versus sunitinib for patients with advanced renal cell carcinoma.
    Powles, Thomas
    Choueiri, Toni K.
    Burotto, Mauricio
    Escudier, Bernard
    Bourlon, Maria Teresa
    Shah, Amishi Yogesh
    Suarez, Cristina
    Hamzaj, Alketa
    Porta, Camillo
    Hocking, Christopher
    Kessler, Elizabeth R.
    Gurney, Howard
    Tomita, Yoshihiko
    Bedke, Jens
    Zhang, Joshua
    Simsek, Burcin
    Scheffold, Christian
    Apolo, Andrea B.
    Motzer, Robert J.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
12345